Pancreatic Cancer Research

ResearcherAsan Medical CenterActive in the last 2 years

Dong‐Wan Seo

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-7525-8151; OpenAlex author ID A5004181585. Sources: ClinicalTrials.gov.

Their work

Papers
11 (first author 1, last author 0)
Trials
1 (principal investigator on 1)
Grants
0
Labs led
0
Collaborators
38
Papers, trials and grants by year

2014: 1 paper · 2015: 1 trial · 2016: none · 2017: none · 2018: 1 paper · 2019: 1 paper · 2020: none · 2021: 1 paper · 2022: 5 papers · 2023: none · 2024: 1 paper · 2025: 1 paper

Papers 11

  1. Survival Outcomes According to NCCN Criteria for Resection Following Neoadjuvant Therapy for Patients with Localized Pancreatic Cancer. Co-author DOI 10.1245/s10434-024-16437-9↗
  2. Comparison of the different versions of NCCN guidelines for predicting margin-negative resection of pancreatic cancer in patients undergoing upfront surgery. Co-author DOI 10.1007/s00261-024-04299-4↗
  3. Prediction of margin-negative resection of pancreatic ductal adenocarcinoma following neoadjuvant therapy: Diagnostic performance of NCCN criteria for resectio… Co-author DOI 10.1002/jhbp.1192↗
  4. Stereotactic Body Radiation Therapy versus Concurrent Chemoradiotherapy for Locally Advanced Pancreatic Cancer: A Propensity Score-Matched Analysis. Co-author DOI 10.3390/cancers14051166↗
  5. Clinical outcomes of EUS-guided radiofrequency ablation for unresectable pancreatic cancer: A prospective observational study. First author DOI 10.4103/eus-d-21-00049↗
  6. Prognosis and Clinical Characteristics of Patients with Pancreatic Ductal Adenocarcinoma Diagnosed by Endoscopic Ultrasonography but Indeterminate on Computed … Co-author DOI 10.5009/gnl210123↗
  7. Corrigendum: Prognosis and Clinical Characteristics of Patients with Pancreatic Ductal Adenocarcinoma Diagnosed by Endoscopic Ultrasonography but Indeterminate… Co-author DOI 10.5009/gnl210123.e↗
  8. CT-determined resectability of borderline resectable and unresectable pancreatic adenocarcinoma following FOLFIRINOX therapy. Co-author DOI 10.1007/s00330-020-07188-8↗
  9. Stereotactic body radiation therapy for locally advanced pancreatic cancer. Co-author DOI 10.1371/journal.pone.0214970↗
  10. Prognosis of Pancreatic Cancer Patients with Synchronous or Metachronous Malignancies from Other Organs Is Better than Those with Pancreatic Cancer Only. Co-author DOI 10.4143/crt.2017.494↗
  11. Survival effect of tumor size and extrapancreatic extension in surgically resected pancreatic cancer: proposal for improved T classification. Co-author DOI 10.1016/j.humpath.2014.06.030↗

Trials 1

  1. Pre-operative Biliary SEMS RCT During Neoadjuvant Therapy Principal investigator NCT02238847↗

Closest collaborators

The 25 strongest of 38 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Changhoon Yoo · 7 shared papers, 2018–2025 · strength 0.95
  2. Kyu‐pyo Kim · 7 shared papers, 2014–2025 · strength 0.92
  3. Song Cheol Kim · 7 shared papers, 2014–2025 · strength 0.87
  4. Seung‐Mo Hong · 6 shared papers, 2014–2025 · strength 0.79
  5. Dae Wook Hwang · 5 shared papers, 2018–2025 · strength 0.71
  6. Jin Hee Kim · 4 shared papers, 2021–2025 · strength 0.68
  7. Jong Keon Jang · 4 shared papers, 2021–2025 · strength 0.68
  8. Seung Soo Lee · 4 shared papers, 2021–2025 · strength 0.68
  9. Jae Ho Byun · 4 shared papers, 2021–2025 · strength 0.68
  10. Hyoung Jung Kim · 4 shared papers, 2021–2025 · strength 0.68
  11. Tae Jun Song · 5 shared papers, 2019–2022 · strength 0.64
  12. Se Jin Choi · 2 shared papers, 2022–2025 · strength 0.37
  13. Jin‐hong Park · 4 shared papers, 2014–2022 · strength 0.31
  14. Sang Soo Lee · 4 shared papers, 2014–2022 · strength 0.31
  15. Do Hyun Park · 2 shared papers, 2022 · strength 0.31
  16. Myung‐Hwan Kim · 2 shared papers, 2022 · strength 0.31
  17. Dongwook Oh · 2 shared papers, 2022 · strength 0.31
  18. Seong‐Hun Kim · 2 shared papers, 2022 · strength 0.26
  19. Jun‐Ho Choi · 2 shared papers, 2022 · strength 0.26
  20. Sung Woo Ko · 2 shared papers, 2022 · strength 0.26
  21. Sang Hyub Lee · 2 shared papers, 2022 · strength 0.26
  22. Jai Hoon Yoon · 2 shared papers, 2022 · strength 0.26
  23. Jae Hee Cho · 2 shared papers, 2022 · strength 0.26
  24. Seung Bae Yoon · 2 shared papers, 2022 · strength 0.26
  25. Hoon Jai Chun · 2 shared papers, 2022 · strength 0.26

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.